Skip to main content
Fig. 1 | The Journal of Headache and Pain

Fig. 1

From: Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study

Fig. 1

a Mean (SD) change from baseline in frequency of headache days. The patient-reported estimate of the number of days in a month with a headache (≥4 h) at each administration visit through visit 8; b Mean (SD) change from baseline in total MSQ score; c Mean (SD) change from baseline in EQ-5D total score. *P < 0.001 Wilcoxon signed rank test for change versus baseline (level of significance, 5%). Abbreviations: Admin, administration; MSQ = Migraine-Specific Quality-of-Life Questionnaire, EQ-5D = EuroQol 5-Dimension Questionnaire

Back to article page